Venture Funding Deals: Year-End Edition
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced December 2019.
You may also be interested in...
Four $2bn+ alliances were penned in July. Topping the list was a potential $2.4bn deal between Arvinas and Pfizer under which the Big Pharma received worldwide co-exclusive rights to develop and commercialize products containing Arvinas’ ARV-471. ARV-471 is in a Phase II dose expansion clinical trial for the treatment of patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Preclinical and early clinical data for ARV-471 as a single agent and in combination with Ibrance was a key contributor in Pfizer’s decision to partner with Arvinas.
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
During Q2, biopharma merger and acquisition value reached $34.7bn and drew in $33bn in potential deal value from alliances. Device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.